Stocks and InvestingStocks and Investing
Wed, October 31, 2018
Tue, October 30, 2018
Mon, October 29, 2018
Fri, October 26, 2018
Thu, October 25, 2018

Christopher Raymond Maintained (VRTX) at Buy with Decreased Target to $201 on, Oct 25th, 2018


Published on 2024-10-26 09:53:29 - WOPRAI, Christopher Raymond
  Print publication without navigation


Christopher Raymond of Raymond James, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Decreased Target from $211 to $201 on, Oct 25th, 2018.

Christopher has made no other calls on VRTX in the last 4 months.



There are 3 other peers that have a rating on VRTX. Out of the 3 peers that are also analyzing VRTX, 1 agrees with Christopher's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Carter Gould of "UBS" Maintained at Hold with Increased Target to $188 on, Thursday, July 26th, 2018


These are the ratings of the 2 analyists that currently disagree with Christopher


  • Robyn Karnauskas of "Citigroup" Maintained at Strong Buy with Increased Target to $206 on, Monday, July 30th, 2018
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $211 on, Thursday, July 26th, 2018